Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: immunotherapeutic kinoids and toxoids - Neovacs

Next Previous
X
Search
Drug Profile

Research programme: immunotherapeutic kinoids and toxoids - Neovacs

Alternative Names: AllergyVACS - Neovacs; Conjugated vaccines - NeoVacs; Debio 0512; E7 toxoid; E7 Δ21-26 toxoid; huTNFα kinoid; iCore toxoid; IL-10 kinoid; IL-13 kinoid; IL-4 kinoid; Interleukin-4 kinoid; Kinoid IL13; Kinoid IL4; Vascular endothelial growth factor kinoid; VEGF-kinoid

Latest Information Update: 28 Dec 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neovacs
  • Developer Debiopharm; Institut Pasteur; Neovacs
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Bronchodilators; Immunotherapies; Vaccines
  • Mechanism of Action Immunomodulators; Immunostimulants; Interleukin 4 inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Age-related macular degeneration; Asthma; Food hypersensitivity; Hypersensitivity; Solid tumours
  • Discontinued Cachexia; Hepatitis C; Human papillomavirus infections

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for preclinical development in Asthma in France
  • 28 Dec 2022 No recent reports of development identified for preclinical development in Food-hypersensitivity in France
  • 28 Nov 2020 No recent reports of development identified for preclinical development in Allergy in France

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top